Actively Recruiting
Analysis of the Role of IgE Proteoforms in Health and Disease
Led by KU Leuven · Updated on 2026-01-09
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of IgE proteoforms in various health conditions, including type I allergy, chronic spontaneous urticaria, recent anaphylaxis, mastocytosis, hereditary alpha tryptasemia, X-linked agammaglobulinemia (XLA), and in patients undergoing desensitization for venom or medication allergies. The study also includes healthy volunteers to compare findings across these groups. This observational study aims to understand how IgE proteoforms differ among these populations and their potential impact. Participants in this study belong to several groups: healthy controls and patients with different allergic or immunological conditions. The study involves collecting blood samples from participants, including those with allergies to medications, venom, food, or airborne allergens, some of whom may be receiving omalizumab treatment. Serial blood sampling is performed to monitor changes over time. During the study, participants will provide blood samples at various time points over four years to evaluate IgE proteoforms. Researchers will collect clinical information regarding allergy severity, medication use, medical history, and laboratory test results. This study involves no treatment interventions and will monitor participants through regular sample collection and clinical assessments to better understand allergy-related immune responses.
CONDITIONS
Brief Title
Analysis of the Role of IgE Proteoforms in Health and Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with chronic spontaneous urticaria, type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, X-linked agammaglobulinemia (XLA), or hereditary alpha tryptasemia
- Healthy adults matched by age and gender to allergic patients
- Participants able to provide informed consent
- Participants with clinical information about their allergy, including severity, medication, medical history, and lab tests
You will not qualify if you...
- No informed consent provided
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Participants provide blood samples for evaluation of IgE proteoforms related to health and allergic diseases.
Visits for blood sample collection depending on cohort and clinical status
Trial Site Locations
Total: 1 location
1
UZ/KU Leuven
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
9
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here